Getinge (GETI) Acquisition presentation summary

Transaction terms

• Definitive agreement to acquire Datascope for $53.00 per share; fully diluted equity value $865 million (SEK 5.8 billion) and implied enterprise value $618 million.

• Offer represented a 34% premium to Datascope’s $39.67 three-month volume-weighted average share price and 12.9x 2007/08 EBITDA of $48 million.

• Closing was expected by year-end 2008, subject to customary regulatory and shareholder approvals.

Strategic rationale

• Combined cardiovascular revenues expected to exceed $650 million, adding critical mass in cardiovascular surgery and cardiac assist markets.

• Revenue synergy potential from complementary products, geographies and sales channels; combination creates a platform for further cardiovascular expansion.

• Highlighted growth opportunities included expanded counterpulsation therapy, peripheral vascular stents, and endografts for AAA and TAA repair.

Datascope business profile

• 2007/08 revenue was $231 million and EBITDA was $48 million, up 8% and 14%, respectively, from 2006/07; the business had ~765 global employees.

• Cardiac Assist generated $189.6 million in 2007/08 sales and held >70% share in IABP technology; products also included vessel-harvesting devices and vascular closure products.

• InterVascular generated $38.4 million in 2007/08 sales; its portfolio included surgical grafts, patches, peripheral stents and endovascular repair products.